Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.520
-0.060 (-3.80%)
Aug 1, 2025, 4:00 PM - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $113.00 million as of August 1, 2025. Its market cap has increased by 950.95% in one year.
Market Cap
113.00M
Enterprise Value
19.89M
1-Year Change
950.95%
Ranking
Category
Stock Price
$1.52
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $113.00M, an increase of 12.49%. That is a compound annual growth rate of 2.59%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 1, 2025 | 113.00M | -48.25% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
| Dec 23, 2020 | 100.46M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 682.35B |
| Johnson & Johnson | 402.82B |
| AbbVie | 334.40B |
| UnitedHealth Group | 241.34B |
| AstraZeneca | 236.88B |
| Novartis AG | 227.02B |
| Abbott Laboratories | 223.66B |
| Novo Nordisk | 221.96B |